ArticleScientific reports2024
AlzGenPred - CatBoost-based gene classifier for predicting Alzheimer's disease using high-throughput sequencing data.
Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- SR2P: an efficient stacking method to predict protein abundance from gene expression in spatial transcriptomics data.bioRxiv : the preprint server for biology · 2026Article
- Diagnosis of Alzheimer's disease with high accuracy via Petri net modeling of signaling pathways.Scientific reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
AD is a progressive neurodegenerative disorder characterized by memory loss. Due to the advancement in next-generation sequencing, an enormous amount of AD-associated genomics data is available. However, the information about the involvement of these genes in AD association is still a research topic. Therefore, AlzGenPred is developed to identify the AD-associated genes using machine-learning. A total of 13,504 features derived from eight sequence-encoding schemes were generated and evaluated using 16 machine learning algorithms. Network-based features significantly outperformed sequence-based features, effectively distinguishing AD-associated genes. In contrast, sequence-based features failed to classify accurately. To improve performance, we generated 24 fused features (6020 D) from sequence-based encodings, increasing accuracy by 5-7% using a two-step lightGBM-based recursive feature selection method. However, accuracy remained below 70% even after hyperparameter tuning. Therefore, network-based features were used to generate the CatBoost-based ML method AlzGenPred with 96.55% accuracy and 98.99% AUROC. The developed method is tested on the AlzGene dataset where it showed 96.43% accuracy. Then the model was validated using the transcriptomics dataset. AlzGenPred provides a reliable and user-friendly tool for identifying potential AD biomarkers, accelerating biomarker discovery, and advancing our understanding of AD. It is available at https://www.bioinfoindia.org/alzgenpred/ and https://github.com/shuklarohit815/AlzGenPred .
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.